Orion Infusion Limited announcements
236 Dhaka Stock Exchange announcements for Orion Infusion Limited (ORIONINFU) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (16).
- Emphasis of Matters
The auditor of the company has given the Emphasis of Matters paragraph in the audited financial statements of the company for the year ended June 30, 2025: To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Orion%20Infusion%20Ltd_2025.pdf
- Resumption after Record Date
Trading of the shares of the company will resume on 02.12.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 01.12.2025 for AGM & EGM.
- Spot for AGM & EGM
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 27.11.2025 to 30.11.2025 and trading of the shares will remain suspended on record date i.e., 01.12.2025 for AGM & EGM.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.57 for July-September 2025 as against Tk. 0.54 for July-September 2024; NOCFPS was Tk. 0.50 for July-September 2025 as against Tk. 0.20 for July-September 2024. NAV per share was Tk. 16.59 as on September 30, 2025 and Tk. 16.02 as on June 30, 2025. (cont.) (Cont. news of ORIONINFU): Reason for deviation in NOCFPS: Net Operating Cash Flow per Share (NOCFPS) has increased compared to the same period of the previous year. This is mainly due to a reduction in financial expenses and effective cost control within operational activities, which had a positive and persistent impact on Net Operating Cash Flow. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 15, 2025 at 3:00 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Dividend Declaration
The Board of Directors has recommended 20% Cash Dividend for General Shareholders only excluding Sponsors and Directors for the year ended June 30, 2025. The Sponsors and Directors hold 8,268,400 shares out of the total 20,359,760 shares of the company and Cash Dividend payable to the General Shareholders is Tk. 24,182,720.00. Date of AGM and EGM: 23.12.2025, Time for AGM: 1:30 PM; Time for EGM: 2:15 PM. (cont.1) (Cont. News of ORIONINFU): The company will hold the EGM for approval of the shareholders regarding the change of the Company's name from Orion Infusion Limited to Orion Infusion PLC. (end) (Cont. News of ORIONINFU): Venue/Mode of AGM and EGM: Digital Platform. Record Date for AGM and EGM: 01.12.2025. The Company has also reported EPS of Tk. 1.72, NAV per share of Tk. 16.02 and NOCFPS of Tk. 1.30 for the year ended June 30, 2025 as against Tk. 2.08, Tk. 15.45 and Tk. 2.82 respectively for the year ended June 30, 2024. (cont.2)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (10.11.2025) following its corporate declaration.
- Board Approval of Investment for Expansion of IV Fluids Production
The company has informed that the Board of Directors of the Company has recently approved a proposal to invest approximately BDT 20.50 crore, including working capital, for the expansion of the existing production line to meet the growing demand for IV Fluids. In preparation for this expansion, the Company is going to commence construction work at its plant located in Maikuli, Rupganj, Narayanganj, which is expected to be completed by December 2026. (cont.) (Cont. News of ORIONINFU): Upon completion, the expansion is expected to increase production capacity by approximately 30%, generating additional annual sales revenue of about BDT 25.50 crore. This expansion will enhance the overall profitability of the Company. The entire investment will be financed through internal sources. (end)
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 09, 2025 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2025.
- Query Response
In response to the DSE query dated 14.08.2025, the company has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.37 for January-March 2025 as against Tk. 0.39 for January-March 2024; EPS was Tk. 1.40 for July 2024-March 2025 as against Tk. 1.45 for July 2023-March 2024. NOCFPS was Tk. 0.75 for July 2024-March 2025 as against Tk. 3.45 for July 2023-March 2024. NAV per share was Tk. 15.71 as on March 31, 2025 and Tk. 15.45 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2025 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 0.49 for October-December 2024 as against Tk. 0.41 for October-December 2023; EPS was Tk. 1.03 for July-December 2024 as against Tk. 1.07 for July-December 2023. NOCFPS was Tk. (0.21) for July-December 2024 as against Tk. 0.38 for July-December 2023. NAV per share was Tk. 15.33 as on December 31, 2024 and Tk. 15.45 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2025 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.